


ADVANCES IN CANCER RESEARCH


VOLUME


124



EMERGING APPLICATIONS OF MOLECULAR IMAGING TO ONCOLOGY

Edited by
Martin G. Pomper
Paul B. Fisher





VOLUME ONE HUNDRED AND TWENTY FOUR

ADVANCES IN CANCER RESEARCH

Emerging Applications of Molecular Imaging to Oncology


Edited by

MARTIN G. POMPER

*Russel H. Morgan Department of Radiology and
Radiological Science, and Sidney Kimmel Comprehensive
Cancer Center, Johns Hopkins University, Baltimore,
Maryland, USA*

PAUL B. FISHER

*Department of Human and Molecular Genetics,
VCU Institute of Molecular Medicine, and VCU Massey
Cancer Center, Virginia Commonwealth University,
School of Medicine, Richmond, Virginia, USA*



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
32 Jamestown Road, London NW1 7BY, UK
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA
225 Wyman Street, Waltham, MA 02451, USA
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK

First edition 2014

Copyright © 2014 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-12-411638-2

ISSN: 0065-230X

For information on all Academic Press publications
visit our website at store.elsevier.com



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org



VOLUME ONE HUNDRED AND TWENTY FOUR

ADVANCES IN **CANCER RESEARCH**

Emerging Applications of Molecular
Imaging to Oncology

CONTRIBUTORS

Eric O. Aboagye

Comprehensive Cancer Imaging Centre, Department of Surgery & Cancer, Imperial College London, London, United Kingdom

Samuel Achilefu

Department of Radiology, Washington University in St. Louis, St. Louis, Missouri, USA

Babak Behnam Azad

Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA

Zaver M. Bhujwala

JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, and Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Kannie W.Y. Chan

F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute; The Russell H. Morgan Department of Radiology and Radiological Sciences, Division of MR Research, and Cellular Imaging Section and Vascular Biology Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Samit Chatterjee

Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA

Xiaoyuan Chen

Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA

Zhihang Chen

JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Swadesh K. Das

Department of Human and Molecular Genetics, and VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA

Sudeep Das

Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY

Luni Emdad

Department of Human and Molecular Genetics; VCU Institute of Molecular Medicine, and VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA

Paul B. Fisher

Department of Human and Molecular Genetics; VCU Institute of Molecular Medicine, and VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA

Sanjiv S. Gambhir

Department of Bioengineering; Molecular Imaging Program at Stanford, The James H Clark Center, Stanford University; Department of Radiology, Stanford University School of Medicine, and Department of Materials Science & Engineering, Stanford University, Stanford, California, USA

Shengkui Gao

Department of Computer Science and Engineering, Washington University in St. Louis, St. Louis, Missouri, USA

Jan Grimm

Molecular Pharmacology and Chemistry Program and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

Viktor Gruev

Department of Computer Science and Engineering, Washington University in St. Louis, St. Louis, Missouri, USA

Edward H. Herskovits

Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore, Maryland, USA

Jiefu Jin

JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Laura M. Kenny

Comprehensive Cancer Imaging Centre, Department of Surgery & Cancer, Imperial College London, London, United Kingdom

Balaji Krishnamachary

JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

David M. Kurtz

Division of Oncology; Division of Hematology, Department of Medicine, Stanford Cancer Institute, and Department of Bioengineering, Stanford University, Stanford, California, USA

Rongguang Liang

College of Optical Sciences, University of Arizona, Tucson, Arizona, USA

Michael T. McMahon

F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, and The Russell H. Morgan Department of Radiology and Radiological Sciences, Division of MR Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Mitchell E. Menezes

Department of Human and Molecular Genetics, Richmond, Virginia, USA

Il Minn

Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA

Suman B. Mondal

Department of Radiology, and Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA

Sridhar Nimmagadda

Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA

Marie-France Penet

JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, and Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Martin G. Pomper

Russell H. Morgan Department of Radiology and Radiological Science, and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA

Devanand Sarkar

Department of Human and Molecular Genetics; VCU Institute of Molecular Medicine, and VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA

Siddik Sarkar

Department of Human and Molecular Genetics, Richmond, Virginia, USA

Avinash Srivatsan

Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA

Daniel L.J. Thorek

Division of Nuclear Medicine, Department of Radiology and Radiological Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA

Keerthi Yarlagadda

Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA

Nan Zhu

College of Optical Sciences, University of Arizona, Tucson, Arizona, USA

PREFACE

As molecular pathways in cancer succumb one by one to increasingly sensitive methods of detection, we can begin to isolate the key drivers of malignancy—with implications for management. Cancer researchers are continually uncovering molecular subsets of what were until recently considered single pathologic entities. Because it is inherently noninvasive, sensitive, and quantitative, molecular imaging enables measurement of biochemistry within tissue and lends itself well to identification of disease subsets and, by extension, precision medicine.

In this volume of *Advances in Cancer Research*, we start by discussing quantitative radiology, and how to extract optimum value out of existing, primarily anatomic clinical imaging studies. We focus on new technologies (nanomedicine, fluorescence-guided surgery, Cerenkov imaging, and smart MR agents) as well as on new targets for detecting cancer directly or for studying the biology of its supporting microenvironment (chemokine receptor 4, hypoxia, pH, and the extracellular matrix). We also address emerging clinical applications, including molecular-genetic imaging, immune cell tracking, assessment of immune therapies, and aspects of tumor metabolism.

A goal of this volume is to communicate the excitement in molecular imaging research as the imaging technologies continue to evolve and adapt to new discoveries in cancer pathogenesis in ways that will enable more precise management of patients suffering from this protean disease.

MARTIN G. POMPER
PAUL B. FISHER

CONTENTS

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xiii</i>
1. Quantitative Radiology: Applications to Oncology	1
Edward H. Herskovits	
1. Introduction	1
2. Radiological Characterization of Tumors	2
3. Quantitative Radiology	15
4. Future Directions	21
5. Conclusion	23
References	23
2. The Intricate Role of CXCR4 in Cancer	31
Samit Chatterjee, Babak Behnam Azad, and Sridhar Nimmagadda	
1. Introduction	32
2. CXCR4/CXCL12 Signaling	33
3. Expression and Physiological Functions of the CXCR4/CXCL12 Axis	35
4. Role of CXCR4 in Cancer	37
5. CXCR4 Antagonists as Therapeutic and Imaging Agents	52
6. Peptides and Peptidomimetics	55
7. Conclusion	64
Acknowledgments	64
References	64
3. Recent Advances in Nanoparticle-Based Nuclear Imaging of Cancers	83
Avinash Srivatsan and Xiaoyuan Chen	
1. Introduction	84
2. Lipid-Based Nanoparticles	89
3. Dendrimers	97
4. Polymers	98
5. Quantum Dots	100
6. Iron Oxide Nanoparticles	102
7. Gold Nanoparticles	108

8. Carbon Nanotubes	110
9. Silica-Based Nanoparticles	112
10. Conclusion	117
References	117
4. Molecular-Genetic Imaging of Cancer	131
Il Minn, Mitchell E. Menezes, Siddik Sarkar, Keerthi Yarlagadda, Swadesh K. Das, Luni Emdad, Devanand Sarkar, Paul B. Fisher, and Martin G. Pomper	
1. Introduction	132
2. Promoters	133
3. Reporters	139
4. Signal Enhancement of Reporters	144
5. Prolonged Expression of Reporters	153
6. Machinery for Gene Delivery	154
7. Size and Immunogenicity	157
8. Concluding Remarks	159
Acknowledgments	160
References	160
5. Real-Time Fluorescence Image-Guided Oncologic Surgery	171
Suman B. Mondal, Shengkui Gao, Nan Zhu, Rongguang Liang, Viktor Gruev, and Samuel Achilefu	
1. Introduction	172
2. Fluorescence Imaging Systems for Intraoperative Procedures	178
3. Current Intraoperative Optical Image Guidance Systems	190
4. Fluorescent Agents Used in Image-Guided Surgery	192
5. Clinical Applications of Fluorescence Image-Guided Surgery	198
6. Future Directions	201
7. Concluding Remarks	202
References	203
6. Cerenkov Imaging	213
Sudeep Das, Jan Grimm, and Daniel L. J. Thorek	
1. Introduction	214
2. Cerenkov Radiation Physics (Simplified)	214
3. Application of Cerenkov in Biological Sciences: CLI	222
4. Conclusion	231
Acknowledgments	231
References	231

7. Molecular Imaging of the Tumor Microenvironment for Precision Medicine and Theranostics	235
Marie-France Penet, Balaji Krishnamachary, Zhihang Chen, Jiefu Jin, and Zaver M. Bhujwalla	
1. Introduction	236
2. Imaging and PM/Theranostics of the Physiological Microenvironment	238
3. The ECM and Its Enzymes	244
4. Endothelial Cells and Tumor Vasculature	246
5. Lymphatic Endothelial Cells, Lymphatics, and Interstitial Pressure	248
6. Stromal Components of the TME and Their Role in PM	249
7. Intraoperative Optical Imaging	251
8. Concluding Remarks	252
Acknowledgments	252
References	252
8. Tracking Cellular and Immune Therapies in Cancer	257
David M. Kurtz and Sanjiv S. Gambhir	
1. Introduction	258
2. Molecular Imaging Approaches to Cancer Immunotherapy	265
3. Radionuclide Methods in the Preclinical and Clinical Settings	270
4. MRI Methods in the Preclinical and Clinical Settings	276
5. Opportunities for Improvements and Future Directions	282
6. Conclusions	288
References	289
9. Developing MR Probes for Molecular Imaging	297
Michael T. McMahon and Kannie W. Y. Chan	
1. General Overview	298
2. T1, T2, T2* Relaxivity-Based Agents	300
3. CEST Probes: Multiple Labeling Frequencies	302
4. ¹⁹ F Probes: Hot-Spot Imaging	308
5. Hyperpolarized Imaging Probes	310
References	316
10. Clinical Translation of Molecular Imaging Agents Used in PET Studies of Cancer	329
Laura M. Kenny and Eric O. Aboagye	
1. Introduction	330
2. FDG—Lessons Learnt	337

3. Stages to Development of a New Radiotracer	339
4. Translating Deregulated Nature-Identical Biochemicals	341
5. Translating Cell Surface and Intracellular Receptors as Predictive Biomarkers	345
6. Translating Probes for Visualization of Life and Death Signals in the Cell	349
7. Translating Tools to Assess Host–Tumor Microenvironment Interactions	356
8. Translating Labeled Drugs and Drug Analogs	359
9. Conclusion	360
Acknowledgments	360
References	361
 <i>Index</i>	 375



Quantitative Radiology: Applications to Oncology

Edward H. Herskovits¹

Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore,
Maryland, USA

¹Corresponding author: e-mail address: ehh@ieece.org

Contents

1. Introduction	1
2. Radiological Characterization of Tumors	2
2.1 Computed tomography	3
2.2 Magnetic resonance	6
2.3 Positron emission tomography	13
3. Quantitative Radiology	15
3.1 Image analysis	15
3.2 Evaluation	20
3.3 Integration	21
4. Future Directions	21
5. Conclusion	23
References	23

Abstract

Oncologists, clinician-scientists, and basic scientists collect computed tomography, magnetic resonance, and positron emission tomography images in the process of caring for patients, managing clinical trials, and investigating cancer biology. As we have developed more sophisticated means for noninvasively delineating and characterizing neoplasms, these image data have come to play a central role in oncology. In parallel, the increasing complexity and volume of these data have necessitated the development of quantitative methods for assessing tumor burden, and by proxy, disease-free survival.



1. INTRODUCTION

Oncologists, clinician-scientists, and basic scientists collect a plethora of data in the process of caring for patients, managing clinical trials, and investigating cancer biology. As we have developed more sophisticated

means for noninvasively delineating and interrogating neoplasms, the resulting image data have come to play a central role in oncology. To understand the current impact and long-term promise of radiology with respect to oncology, it may help to characterize the nature of the information sought as we diagnose and treat cancer patients.

The ultimate goal of patient care in oncology is to maximize disease-free survival (DFS)—or, barring that, progression-free survival (PFS)—while minimizing the morbidity of treatment (i.e., to maximize quality-adjusted life years). Ignoring intercurrent illnesses and treatment morbidity for the sake of this discussion, we take PFS to be a function of tumor burden, which can be decomposed into two independent factors: the number of tumor cells and the malignant potential of each cell. For many years, the former—extent—was determined via exploratory surgery and summarized as tumor stage, and the latter—grade—was determined by pathologists from what was hoped to be a biologically representative sample obtained during this operation. Advances in radiology first became evident with respect to staging, for the simple reason that it is much easier to generate images that show macroscopic groups of cells than it is to generate images that show how these cells are likely to behave. Only in the last decade has radiology begun to offer information regarding tumor biology, and such information still pales in comparison with that obtained from histopathology and genetic analysis.

In parallel with the increasing complexity of image data, there has been steady progress in the quantification of these data. Although clinical radiology reports are unfortunately replete with verbiage such as “large mass in the right frontal lobe,” researchers have begun to deliver on the promise of computer-based methods for quantification of tumor extent and have also developed quantitative or semiquantitative methods for characterizing tumor biology. The premise underlying such efforts is that quantitative—rather than qualitative—indications of tumor extent and biology render more precise prediction of DFS, thereby promising superior patient care and assessment of therapy. Herein I explore the arc of radiology’s contributions to oncology, both in terms of the information provided and efforts to quantify this information, with the expectation that such exploration will shed light on future developments in oncology research and practice.



2. RADIOLOGICAL CHARACTERIZATION OF TUMORS

The advent of computed tomography (CT) revolutionized the staging of solid tumors; since then, the quality and range of information provided to